The company's drug discovery platform targets essential receptors and proteins, and its lead drug candidate, dipraglurant, is in a clinical trial for Parkinson's disease levodopa induced dyskinesia, with another clinical trial expected to be initiated for blepharospasm in Q3 2021. Addex also has a third clinical program for the treatment of epilepsy, as well as preclinical programs for various disorders. The company operates in Switzerland and Europe and is listed on the SIX Swiss Exchange and NASDAQ Capital Market.